Loading
A phase 3 trial testing Oleclumab in non-small-cell lung cancer, active and no longer recruiting.
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05221840, led by AstraZeneca, and active but no longer recruiting on the registry. Official title: A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy. Planned enrolment is 1051 participants (actual). The study started in 2022-02-07 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Monalizumab, Oleclumab, Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Oleclumab, Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Monalizumab, Oleclumab, AstraZeneca, Non-small-cell lung cancer.
Shares Monalizumab, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Oleclumab, AstraZeneca, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/